Loring Wolcott & Coolidge Fiduciary Advisors LLP MA reduced its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 139,665 shares of the company’s stock after selling 1,483 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in IDEXX Laboratories were worth $21,841,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the company. LS Investment Advisors LLC grew its position in shares of IDEXX Laboratories by 8.2% in the 3rd quarter. LS Investment Advisors LLC now owns 4,846 shares of the company’s stock worth $754,000 after buying an additional 368 shares during the last quarter. Norinchukin Bank The lifted its stake in shares of IDEXX Laboratories by 6.2% in the 3rd quarter. Norinchukin Bank The now owns 6,495 shares of the company’s stock valued at $1,010,000 after purchasing an additional 379 shares during the period. Cubist Systematic Strategies LLC lifted its stake in shares of IDEXX Laboratories by 5.3% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 7,662 shares of the company’s stock valued at $1,191,000 after purchasing an additional 384 shares during the period. Catalyst Capital Advisors LLC lifted its stake in shares of IDEXX Laboratories by 2.3% in the 4th quarter. Catalyst Capital Advisors LLC now owns 17,600 shares of the company’s stock valued at $2,752,000 after purchasing an additional 400 shares during the period. Finally, Synovus Financial Corp lifted its stake in shares of IDEXX Laboratories by 18.1% in the 3rd quarter. Synovus Financial Corp now owns 2,655 shares of the company’s stock valued at $408,000 after purchasing an additional 406 shares during the period. Hedge funds and other institutional investors own 86.50% of the company’s stock.

A number of research firms have recently commented on IDXX. BidaskClub cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 9th. Zacks Investment Research upgraded IDEXX Laboratories from a “hold” rating to a “strong-buy” rating and set a $214.00 target price for the company in a research note on Monday, February 5th. Bank of America raised their target price on IDEXX Laboratories from $200.00 to $220.00 and gave the company a “buy” rating in a research note on Friday, February 2nd. Piper Jaffray Companies raised their target price on IDEXX Laboratories to $211.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. Finally, Canaccord Genuity restated a “buy” rating and issued a $210.00 target price on shares of IDEXX Laboratories in a research note on Monday, January 29th. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and one has given a strong buy rating to the company. IDEXX Laboratories currently has an average rating of “Buy” and a consensus target price of $194.00.

In other IDEXX Laboratories news, CEO Jonathan W. Ayers sold 18,000 shares of IDEXX Laboratories stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $153.61, for a total transaction of $2,764,980.00. Following the completion of the transaction, the chief executive officer now owns 1,064,573 shares in the company, valued at $163,529,058.53. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Jonathan W. Ayers sold 22,000 shares of IDEXX Laboratories stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $177.52, for a total value of $3,905,440.00. Following the transaction, the chairman now owns 1,077,112 shares of the company’s stock, valued at approximately $191,208,922.24. The disclosure for this sale can be found here. Insiders have sold 104,762 shares of company stock valued at $17,967,464 in the last quarter. 2.77% of the stock is owned by company insiders.

IDEXX Laboratories, Inc. (NASDAQ IDXX) opened at $175.39 on Wednesday. The stock has a market capitalization of $15,268.51, a price-to-earnings ratio of 59.66, a price-to-earnings-growth ratio of 2.15 and a beta of 0.58. IDEXX Laboratories, Inc. has a one year low of $140.63 and a one year high of $198.73. The company has a debt-to-equity ratio of -11.26, a quick ratio of 0.80 and a current ratio of 0.97.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Thursday, February 1st. The company reported $0.77 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.04. The business had revenue of $506.00 million during the quarter, compared to analysts’ expectations of $490.51 million. IDEXX Laboratories had a negative return on equity of 432.19% and a net margin of 13.36%. The firm’s quarterly revenue was up 14.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.58 earnings per share. equities research analysts forecast that IDEXX Laboratories, Inc. will post 4.09 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2018/02/14/idexx-laboratories-inc-idxx-stake-decreased-by-loring-wolcott-coolidge-fiduciary-advisors-llp-ma.html.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.